Rapport Therapeutics, Inc.
27.01-0.38 (-1.39%)
Oct 30, 10:28:49 AM EDT · NasdaqGM · RAPP · USD
Key Stats
Market Cap
1.25BP/E (TTM)
22.51Basic EPS (TTM)
1.20Dividend Yield
0%Recent Filings
8-K
Rapport prices $260M stock offering
Rapport Therapeutics priced its underwritten public offering of 9,615,385 common shares at $26.00 each on September 9, 2025, expecting to net $234.7 million after fees. The deal, closing around September 11, bolsters funding for clinical trials of RAP-219 and R&D efforts. Underwriters hold a 30-day option for 1,442,307 more shares. Yet market volatility could delay closure.
8-K
ATM prospectus terminated
Rapport Therapeutics terminated its at-the-market (ATM) sales agreement prospectus effective September 8, 2025, halting any potential issuance of common stock through Leerink Partners and Cantor Fitzgerald. No shares were sold under the July 1, 2025, agreement prior to termination. The Sales Agreement itself persists, pending a new prospectus. This move signals a pause in equity fundraising efforts.
8-K
Positive RAP-219 Phase 2a results
Rapport Therapeutics announced positive topline results from its Phase 2a trial of RAP-219 in drug-resistant focal onset seizures on September 8, 2025, showing 85.2% of patients achieved ≥30% reduction in long episodes and 77.8% cut clinical seizures (p=0.01), with 24% reaching seizure freedom. The drug proved generally well-tolerated, with no serious adverse events and only 10% discontinuation. RAP-219 advances to Phase 3 trials in Q3 2026. Yet risks linger in regulatory approvals.
10-Q
Q2 FY2025 results
Rapport Therapeutics posted a Q2 net loss of $26.7M, up 47.6% y/y from $18.1M (derived), driven by R&D expenses climbing 44.7% to $22.7M on RAP-219 trial ramp-up and headcount growth, while G&A rose 33.4% to $6.8M amid stock-based comp. Operating loss widened to $29.5M from $20.8M y/y, offset by $2.8M interest income; diluted EPS fell to $(0.75) from $(1.70), reconciling with 35.4M weighted shares and anti-dilutive options excluded. Cash and short-term investments stood at $260.4M at quarter-end, funding ops through 2026 with no debt. No M&A or non-GAAP metrics disclosed in the 10-Q. Regulatory hurdles persist, as the FDA's clinical hold on RAP-219's DPNP trial underscores development risks.
8-K
Q2 loss widens; trials advance
Rapport Therapeutics reported Q2 2025 net loss of $26.7 million, up from $18.1 million last year, driven by higher R&D costs for clinical programs. RAP-219's Phase 2a trial in drug-resistant focal onset seizures is fully enrolled, with topline results due in September 2025; the bipolar mania Phase 2 trial has started, eyeing data in early 2027. Cash stands at $260.4 million, funding operations through 2026. Pivotal readout looms.
CTNM
Contineum Therapeutics, Inc.
10.90-0.13
NEUP
Neuphoria Therapeutics Inc.
4.58-0.13
NLSP
NLS Pharmaceutics Ltd.
0.74-0.31
NMRA
Neumora Therapeutics, Inc.
2.50-0.09
NRXP
NRX Pharmaceuticals, Inc.
3.05+0.05
NVCT
Nuvectis Pharma, Inc.
6.77+0.34
OVID
Ovid Therapeutics Inc.
1.45-0.04
RAPT
RAPT Therapeutics, Inc.
29.78-0.35
RPTX
Repare Therapeutics Inc.
1.78-0.01
RVPH
Reviva Pharmaceuticals Holdings
0.59+0.01